155 related articles for article (PubMed ID: 28160012)
1. First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.
Helmer E; Watling M; Jones E; Tytgat D; Jones M; Allen R; Payne A; Koch A; Healy E
Eur J Clin Pharmacol; 2017 May; 73(5):581-591. PubMed ID: 28160012
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
Juarez M; Diaz N; Johnston GI; Nayar S; Payne A; Helmer E; Cain D; Williams P; Devauchelle-Pensec V; Fisher BA; Giacomelli R; Gottenberg JE; Guggino G; Kvarnström M; Mariette X; Ng WF; Rosas J; Sánchez Bursón J; Triolo G; Barone F; Bowman SJ
Rheumatology (Oxford); 2021 Mar; 60(3):1364-1375. PubMed ID: 32949140
[TBL] [Abstract][Full Text] [Related]
3. PI3Kδ Sustains Keratinocyte Hyperproliferation and Epithelial Inflammation: Implications for a Topically Druggable Target in Psoriasis.
Mercurio L; Morelli M; Scarponi C; Scaglione GL; Pallotta S; Albanesi C; Madonna S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685616
[TBL] [Abstract][Full Text] [Related]
4. Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3K
Allen RA; Brookings DC; Powell MJ; Delgado J; Shuttleworth LK; Merriman M; Fahy IJ; Tewari R; Silva JP; Healy LJ; Davies GCG; Twomey B; Cutler RM; Kotian A; Crosby A; McCluskey G; Watt GF; Payne A
J Pharmacol Exp Ther; 2017 Jun; 361(3):429-440. PubMed ID: 28442583
[TBL] [Abstract][Full Text] [Related]
5. Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases.
Chen S; Paveley R; Kraal L; Sritharan L; Stevens E; Dedi N; Shock A; Shaw S; Juarez M; Yeremenko N; Baeten D; Payne A
J Autoimmun; 2020 Jul; 111():102435. PubMed ID: 32360069
[TBL] [Abstract][Full Text] [Related]
6. A Dual-Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [
Helmer E; Nicolas JM; Long J; Roffel AF; Jones E; Chanteux H; Diaz N; Garratt H; Bosje T
J Clin Pharmacol; 2017 Dec; 57(12):1582-1590. PubMed ID: 28650526
[TBL] [Abstract][Full Text] [Related]
7. Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions.
Nicolas JM; Chanteux H; Nicolaï J; Brouta F; Viot D; Rosseels ML; Gillent E; Bonnaillie P; Mathy FX; Long J; Helmer E
Eur J Pharm Sci; 2020 Jan; 142():105122. PubMed ID: 31678424
[TBL] [Abstract][Full Text] [Related]
8. Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.
Diaz N; Juarez M; Cancrini C; Heeg M; Soler-Palacín P; Payne A; Johnston GI; Helmer E; Cain D; Mann J; Yuill D; Conti F; Di Cesare S; Ehl S; Garcia-Prat M; Maccari ME; Martín-Nalda A; Martínez-Gallo M; Moshous D; Santilli V; Semeraro M; Simonetti A; Suarez F; Cavazzana M; Kracker S
J Immunol; 2020 Dec; 205(11):2979-2987. PubMed ID: 33115853
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
11. Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects.
Patel DR; Urva S; Ho S; Buckman CJ; Ma Y; Lim J; Sissons SE; Zuniga MS; Philips D; Cox K; Dairaghi DJ
Clin Transl Sci; 2021 May; 14(3):1037-1048. PubMed ID: 33382916
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
[TBL] [Abstract][Full Text] [Related]
13. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
14. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Covington P; Christopher R; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):499-512. PubMed ID: 18405788
[TBL] [Abstract][Full Text] [Related]
16. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.
Cahn A; Hamblin JN; Begg M; Wilson R; Dunsire L; Sriskantharajah S; Montembault M; Leemereise CN; Galinanes-Garcia L; Watz H; Kirsten AM; Fuhr R; Hessel EM
Pulm Pharmacol Ther; 2017 Oct; 46():69-77. PubMed ID: 28823947
[TBL] [Abstract][Full Text] [Related]
17. Expression of PI3K Signaling Associated with T Cells in Psoriasis Is Inhibited by Seletalisib, a PI3Kδ Inhibitor, and Is Required for Functional Activity.
Yager N; Haddadeen C; Powell M; Payne A; Allen R; Healy E
J Invest Dermatol; 2018 Jun; 138(6):1435-1439. PubMed ID: 29307594
[No Abstract] [Full Text] [Related]
18. The phosphoinositide-3-kinase (PI3K)-delta inhibitor seletalisib impairs monocyte-derived dendritic cells maturation, APC function, and promotes their migration to CCR7 and CXCR4 ligands.
Scopelliti F; Mercurio L; Cattani C; Dimartino V; Albanesi C; Costanzo G; Mirisola C; Madonna S; Cavani A
J Leukoc Biol; 2022 Sep; 112(3):383-393. PubMed ID: 35199885
[TBL] [Abstract][Full Text] [Related]
19. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
